Genetic Technologies Limited (GENE) Stock Analysis
DELISTED
What happened to Genetic Technologies Limited (GENE) stock?
Genetic Technologies Limited (GENE) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
Market cap $111M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Genetic Technologies Limited (GENE). Genetic Technologies Limited is a molecular diagnostics company focused on predictive testing and assessment tools for women's health. Their lead product, BREVAGenplus, assesses non-hereditary breast cancer risk, with expansion into other disease risk assessments.
Last analyzed: Mar 16, 2026Genetic Technologies Limited (GENE) Healthcare & Pipeline Overview
Genetic Technologies Limited ADR Information Sponsored
Genetic Technologies Limited (GENE) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 2
- ADR Ratio: 1:1
More about this archive record
Can I still buy GENE shares?
No. GENE stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for GENE elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before GENE stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Genetic Technologies Limited. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.